Kampen KR - Search Results

1

Acute myeloid leukemia in the vascular niche.

Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, Saki N. Cogle CR, et al. Among authors: kampen kr. Cancer Lett. 2016 Oct 1;380(2):552-560. doi: 10.1016/j.canlet.2015.05.007. Epub 2015 May 8. Cancer Lett. 2016. PMID: 25963886 Review.

2

Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia.

Kruizinga RC, de Jonge HJ, Kampen KR, Walenkamp AM, de Bont ES. Kruizinga RC, et al. Among authors: kampen kr. Pediatr Blood Cancer. 2011 Feb;56(2):294-7. doi: 10.1002/pbc.22783. Pediatr Blood Cancer. 2011. PMID: 20981743

3

Vascular endothelial growth factor signaling in acute myeloid leukemia.

Kampen KR, Ter Elst A, de Bont ES. Kampen KR, et al. Cell Mol Life Sci. 2013 Apr;70(8):1307-17. doi: 10.1007/s00018-012-1085-3. Epub 2012 Jul 26. Cell Mol Life Sci. 2013. PMID: 22833169 Free PMC article. Review.

4

Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.

Weidenaar AC, Ter Elst A, Kampen KR, Meeuwsen-de Boer T, Kamps WA, Schuringa JJ, de Bont ES. Weidenaar AC, et al. Among authors: kampen kr. Mol Cancer Res. 2013 Apr;11(4):339-48. doi: 10.1158/1541-7786.MCR-12-0113. Epub 2013 Feb 7. Mol Cancer Res. 2013. PMID: 23393162

5

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. Kampen KR, et al. Mol Cancer Res. 2015 Jun;13(6):982-92. doi: 10.1158/1541-7786.MCR-14-0660-T. Epub 2015 May 5. Mol Cancer Res. 2015. PMID: 25944917 Free PMC article.

6

Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.

Shirzad R, Shahrabi S, Ahmadzadeh A, Kampen KR, Shahjahani M, Saki N. Shirzad R, et al. Among authors: kampen kr. Clin Transl Oncol. 2016 Oct;18(10):957-71. doi: 10.1007/s12094-015-1477-6. Epub 2016 Jan 7. Clin Transl Oncol. 2016. PMID: 26742939 Review.

7

VEGFC Antibody Therapy Drives Differentiation of AML.

Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM. Kampen KR, et al. Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5. Cancer Res. 2018. PMID: 30185550

8

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling.

Weidenaar AC, ter Elst A, Kampen KR, Meeuwsen-de Boer TG, de Jonge HJ, Scherpen FJ, den Dunnen WF, Kamps WA, de Bont ES. Weidenaar AC, et al. Among authors: kampen kr. Br J Cancer. 2011 Dec 6;105(12):1856-63. doi: 10.1038/bjc.2011.460. Epub 2011 Nov 1. Br J Cancer. 2011. PMID: 22045186 Free PMC article.

9

The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology.

Kampen KR. Kampen KR. Anticancer Drugs. 2012 Apr;23(4):347-54. doi: 10.1097/CAD.0b013e32835004ac. Anticancer Drugs. 2012. PMID: 22261741 Review.

10

Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

Kampen KR, Ter Elst A, Mahmud H, Scherpen FJ, Diks SH, Peppelenbosch MP, de Haas V, Guryev V, de Bont ES. Kampen KR, et al. Leukemia. 2014 Mar;28(3):589-99. doi: 10.1038/leu.2013.342. Epub 2013 Nov 18. Leukemia. 2014. PMID: 24240200

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page